Lakefront Biotherapeutics (LKFT) EBITDA (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported EBITDA for 13 consecutive years, with -$74.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 55.33% year-over-year to -$74.6 million; the TTM figure through Mar 2026 stood at $446.3 million (up 329.45% YoY), while the FY2025 annual figure was $343.4 million, up 270.65% from the prior year.
• EBITDA eased to -$74.6 million in Q1 2026 per LKFT's latest filing, from $881.4 million in the prior quarter.
• Across five years, EBITDA topped out at $881.4 million in Q4 2025 and bottomed at -$538.5 million in Q3 2025.
• Historically, EBITDA has averaged $15.6 million across 5 years, with a median of -$15.5 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA jumped 5629.05% — and 2024, when it slumped 1276.11%.
• Lakefront Biotherapeutics' EBITDA stood at $4.1 million in 2022, then surged by 5629.05% to $233.8 million in 2023, then slumped by 67.41% to $76.2 million in 2024, then surged by 1056.85% to $881.4 million in 2025, then sank by 108.46% to -$74.6 million in 2026.
• Business Quant data shows LKFT's EBITDA at -$74.6 million in Q1 2026, $881.4 million in Q4 2025, and -$538.5 million in Q3 2025.